文献速递神经核医学放射性药物与辐射防护

人脑β-分泌酶1的PET显像:[18F]PF-06684511的辐射剂量学、定量与重测信度检验

PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-06

本研究在健康志愿者中评估[18F]PF-06684511全脑分布、辐射剂量学、定量方法及重测可靠性。剂量学组5例,全身PET 366分钟共4次PET-CT;重测组8例,脑PET 123分钟,间隔5至19天。2TCM定量最适,VT重测变异16.5%,ICC 0.496,有效剂量24.7 μSv/MBq,结论为该配体适用于人脑BACE1水平测量。

要点

  • [18F]PF-06684511有效剂量24.7±0.8 μSv/MBq,与其他18F配体相似,可重复PET测量
  • 2TCM为最适定量方法,前扣带皮层VT最高,小脑最低
  • VT重测变异16.5%,ICC 0.496,与其他无参考区配体相似但ICC较低

核心结论

  • [18F]PF-06684511有效剂量与其他18F放射性配体相似,允许重复PET测量。
  • 2TCM是最适定量方法,VT重测变异与其他无参考区配体相似但ICC较低。
  • 数据表明[18F]PF-06684511是测量人脑BACE1水平的合适放射性配体。

研究设计与样本

  • 剂量学研究纳入5例受试者,全身PET 366分钟共4次PET-CT,采用男性成人模型估算吸收剂量。
  • 重测研究纳入8例受试者,脑PET测量123分钟,测试与重测间隔5至19天。
  • 以1T、2T房室模型和图解分析估算总分布容积VT,计算重测变异TRV和组内相关系数ICC。

主要发现

  • 剂量学研究中肝脏摄取最高(0.5小时25.2±2.3 %ID),胰腺剂量最大(92.9±52.2 μSv/MBq)。
  • 计算的有效剂量ED为24.7±0.8 μSv/MBq。
  • 重测研究中2TCM良好描述时间-放射性曲线;VT(2TCM)在前扣带皮层最高(6.28±1.09与6.85±0.81),小脑最低(4.23±0.88与4.20±0.75)。
  • VT(2TCM)平均TRV为16.5%(12.4-20.5%),ICC为0.496(0.291-0.644)。

关键数值与推荐

  • 有效剂量ED为24.7±0.8 μSv/MBq。
  • 肝脏摄取0.5小时为25.2±2.3 %ID,胰腺剂量为92.9±52.2 μSv/MBq。
  • VT(2TCM)平均TRV为16.5%(12.4-20.5%),ICC为0.496(0.291-0.644)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Beta-secretase 1 (BACE1) enzyme is implicated in the pathophysiology of Alzheimer's disease. [18F]PF-06684511 is a positron emission tomography (PET) radioligand for imaging BACE1. Despite favorable brain kinetic properties, the effective dose (ED) of [18F]PF-06684511 estimated in non-human primates was relatively high. This study was therefore designed to evaluate the whole-body distribution, dosimetry, quantification, and test-retest reliability of imaging brain BACE1 with [18F]PF-06684511 in healthy volunteers. METHODS: Five subjects were studied for the dosimetry study. Whole-body PET was performed for 366 min with 4 PET-CT sessions. Estimates of the absorbed radiation dose were calculated using the male adult model. Eight subjects participated in the test-retest study. Brain PET measurements were conducted for 123 min with an interval of 5 to 19 days between test and retest conditions. The total distribution volume (VT) was estimated with one-tissue (1T), two-tissue (2T), compartment model (CM), and graphical analysis. Test-retest variability (TRV) and intraclass correlation coefficient (ICC) of VT were calculated as reliability measures. RESULTS: In the dosimetry study, the highest uptake was found in the liver (25.2 ± 2.3 %ID at 0.5 h) and the largest dose was observed in the pancreas (92.9 ± 52.2 μSv/MBq). The calculated ED was 24.7 ± 0.8 μSv/MBq. In the test-retest study, 2TCM described the time-activity curves well. VT (2TCM) was the highest in the anterior cingulate cortex (6.28 ± 1.09 and 6.85 ± 0.81) and the lowest in the cerebellum (4.23 ± 0.88 and 4.20 ± 0.75). Mean TRV and ICC of VT (2TCM) were 16.5% (12.4-20.5%) and 0.496 (0.291-0.644). CONCLUSION: The ED of [18F]PF-06684511 was similar to other 18F radioligands, allowing repeated PET measurements. 2TCM was the most appropriate quantification method. TRV of VT was similar to other radioligands without a reference region, albeit with lower ICC. These data indicated that [18F]PF-06684511 is a suitable radioligand to measure BACE1 level in the human brain. TRIAL REGISTRATION: EudraCT 2016-001110-19 (registered 2016-08-08).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Arakawa R, Takano A, Stenkrona P, et al. PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511. Eur J Nucl Med Mol Imaging. 2020. PMID: 32140803. doi:10.1007/s00259-020-04739-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。